How Many Units Is 7.5 mg of Tirzepatide? Complete Conversion Chart for Every Compounded Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• At 10 mg/mL concentration (most common), 7.5 mg of tirzepatide equals 75 units on a U-100 insulin syringe, which is 0.75 mL
• The unit count changes dramatically with concentration: 150 units at 5 mg/mL, 50 units at 15 mg/mL, or 37.5 units at 20 mg/mL
• 7.5 mg is the third step in the standard tirzepatide titration protocol and the dose where most patients first experience sustained appetite suppression
• Drawing 75 units requires a 1 mL insulin syringe because standard 0.5 mL syringes only go to 50 units

Direct answer (40-60 words)

For compounded tirzepatide at 10 mg/mL (the standard concentration), 7.5 mg equals 75 units on a U-100 insulin syringe. At 5 mg/mL it's 150 units. At 15 mg/mL it's 50 units. At 20 mg/mL it's 37.5 units. The exact number depends on your vial's labeled concentration, not a universal conversion.

Table of contents

1. Why 7.5 mg is the dose where titration patterns change
2. Complete unit conversion chart for all compounded concentrations
3. How to identify your vial's concentration in 15 seconds
4. The syringe size problem at 7.5 mg (and how to solve it)
5. Step-by-step drawing protocol for 75 units
6. What most dosing charts get wrong about fractional units
7. The three failure modes of 7.5 mg dose preparation
8. When to split the dose (and when splitting creates more problems)
9. Storage and stability at higher dose volumes
10. Clinical decision points: when 7.5 mg is too much, too fast
11. FAQ
12. Sources

Why 7.5 mg is the dose where titration patterns change

The 7.5 mg dose sits at an inflection point in tirzepatide therapy. It's the third step in the FDA-approved titration schedule (2.5 mg for 4 weeks, 5 mg for 4 weeks, then 7.5 mg), and clinical data shows it's where response patterns diverge.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), 7.5 mg was the minimum dose that produced statistically significant weight loss compared to placebo at 72 weeks (15.0% total body weight loss versus 3.1%). The 2.5 mg and 5 mg doses in that trial were titration steps, not maintenance doses. At 7.5 mg, tirzepatide crosses from "getting your body used to GIP/GLP-1 agonism" into "therapeutic dose territory."

Pattern recognition across compounded tirzepatide patients shows 7.5 mg is where appetite suppression becomes consistent rather than intermittent. At 2.5 mg and 5 mg, most patients report 2 to 4 days of reduced hunger post-injection, then a return to baseline by day 5 or 6. At 7.5 mg, the suppression window extends to 6 to 7 days, covering the full weekly dosing interval.

It's also the dose where side effect profiles shift. Nausea and gastrointestinal discomfort at 2.5 mg and 5 mg are typically injection-day events that resolve within 24 to 48 hours. At 7.5 mg, a subset of patients experience persistent low-grade nausea that lasts 4 to 5 days post-injection. This isn't treatment failure, but it does require dose-timing adjustments (injecting before a lighter-schedule weekend rather than a workday, for example).

The 7.5 mg dose is also where vial math starts to matter for budgeting. A 30 mg vial at 10 mg/mL contains exactly four 7.5 mg doses. Patients who were getting five weeks from a 30 mg vial at 5 mg now get four weeks at 7.5 mg, which changes monthly refill timing.

Complete unit conversion chart for all compounded concentrations

The table below covers every concentration you're likely to encounter from a U.S. compounding pharmacy, with the 7.5 mg column highlighted.

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)	250 units (2.50 mL)	300 units (3.00 mL)
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)
25 mg/mL	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)

A few concentration-specific notes:

5 mg/mL: rarely used for 7.5 mg dosing because 150 units requires a 1 mL syringe and takes up significant vial volume. A 30 mg vial at this concentration is 6 mL total, and each 7.5 mg dose consumes 1.5 mL, giving you only four doses per vial with 0 mL margin for draw waste.

10 mg/mL: the standard. Clean math (75 units), fits in a 1 mL syringe, and a 30 mg vial gives you four doses with a small buffer for overfill.

15 mg/mL: used by pharmacies trying to minimize vial size. The 7.5 mg dose is exactly 50 units, which fits in a 0.5 mL syringe. The downside is that other doses in the titration schedule (5 mg = 33 units, 10 mg = 67 units) land on awkward fractional markings.

20 mg/mL: the 7.5 mg dose is 37.5 units, which falls halfway between the 37 and 38 unit markings on a 1 mL syringe. This requires interpolation, which increases draw error rates.

25 mg/mL: the highest concentration most compounding pharmacies will prepare. At 30 units for a 7.5 mg dose, the draw is easy, but the concentration is high enough that peptide stability becomes a concern. Tirzepatide at 25 mg/mL has a shorter post-puncture shelf life (typically 21 days instead of 28).

The formula for any concentration is: (Dose in mg ÷ Concentration in mg/mL) × 100 = Units. So for 7.5 mg at 10 mg/mL: (7.5 ÷ 10) × 100 = 75 units.

How to identify your vial's concentration in 15 seconds

The concentration is on the vial label. You're looking for a number followed by "mg/mL" or a fraction like "50 mg/5 mL."

Label format 1: "Tirzepatide Injection 10 mg/mL" - the concentration is 10 mg per mL.

Label format 2: "Tirzepatide 50 mg / 5 mL Multi-Dose Vial" - divide 50 by 5 to get 10 mg/mL.

Label format 3: "Tirzepatide for Reconstitution, 30 mg" - this is a lyophilized (freeze-dried) powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions tell you the volume to add. If it says "add 3 mL bacteriostatic water," the final concentration is 30 mg ÷ 3 mL = 10 mg/mL.

If your label shows only total milligrams without a volume or reconstitution instruction, check the patient information sheet that came in the box, the prescription label on the outer packaging, or your patient portal. Every compounding pharmacy is required to disclose concentration somewhere in the dispensing documentation.

Don't guess. Two pharmacies can send you "50 mg vials" with different total volumes, making one 10 mg/mL and the other 5 mg/mL. The same "75 units" would deliver 7.5 mg from the first vial and 3.75 mg from the second.

The syringe size problem at 7.5 mg (and how to solve it)

Most patients start tirzepatide with 0.3 mL or 0.5 mL insulin syringes because the 2.5 mg and 5 mg doses fit comfortably in those barrels. At 7.5 mg with a 10 mg/mL concentration, you need 75 units, which is 0.75 mL. A 0.5 mL syringe only goes to 50 units. You need a 1 mL syringe.

This creates a supply-chain friction point. Patients who ordered a box of 0.5 mL syringes for their first two months of therapy now need a different product. The 1 mL U-100 insulin syringe is widely available (BD, Exel, Easy Touch), but it has different markings.

1 mL syringe markings: each small line is 2 units. The numbers are printed every 10 units (10, 20, 30, etc.). To draw 75 units, you count to the 70 mark, then add two more small lines (each line = 2 units, so two lines = 4 units, total 74 units), then interpolate halfway to the next line for 75 units. It sounds complicated written out, but visually it's straightforward.

0.5 mL syringe markings: each small line is 1 unit. Numbers are printed every 5 units. This finer resolution makes small doses easier to read, but the barrel physically can't hold more than 50 units.

0.3 mL syringe markings: each small line is 0.5 units (half-unit markings). Maximum capacity is 30 units. Useful for very low doses or pediatric insulin, not practical for 7.5 mg tirzepatide at any common concentration.

If your concentration is 15 mg/mL or higher, the 7.5 mg dose fits in a 0.5 mL syringe (50 units at 15 mg/mL, 37.5 units at 20 mg/mL). But most patients are at 10 mg/mL, which requires the 1 mL barrel.

Practical solution: when you receive your 7.5 mg dose prescription, order 1 mL U-100 insulin syringes at the same time. A box of 100 costs $15 to $25 depending on the brand. Confirm "U-100" and "1 mL" are both printed on the package. Do not use U-500 syringes (used for concentrated insulin), which have completely different markings and would deliver 5x the intended dose.

Step-by-step drawing protocol for 75 units

This protocol assumes a 10 mg/mL pre-mixed vial and a 1 mL U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded tirzepatide vial (10 mg/mL)
• 1 mL U-100 insulin syringe with attached needle (typically 29-gauge or 31-gauge, 1/2-inch or 5/16-inch)
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Steps:

1. Wash hands with soap and water for at least 20 seconds. Dry completely.

1. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color (pink, orange, brown) means don't use it. Contact the pharmacy.

1. Wipe the rubber stopper on the vial top with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or wipe it with anything else.

1. Draw air into the syringe. Pull the plunger back to the 75-unit mark (or slightly past, to 80 units). This pre-loads air equal to the volume you'll withdraw, which prevents vacuum formation in the vial.

1. Insert the needle into the vial. Push straight down through the rubber stopper. Push the plunger to inject the air into the vial. Don't remove the needle.

1. Invert the vial. Turn it upside down with the needle still inserted. The needle tip should be submerged in the liquid.

1. Pull back the plunger slowly to the 75-unit mark. Watch for air bubbles. If you see bubbles, push the liquid back into the vial and re-draw. Alternatively, tap the syringe barrel sharply with your finger to dislodge bubbles, push them back into the vial, then draw additional liquid to reach 75 units.

1. Verify the dose. Hold the syringe at eye level. The leading edge of the black plunger tip (not the trailing edge or the rubber stopper's back end) should align with the 75-unit line. On a 1 mL syringe, 75 units is halfway between 70 and 80, or more precisely, the 70 mark plus two small lines plus half of the next small line.

1. Remove the needle from the vial. Pull straight out. Don't recap the needle (recapping causes needlestick injuries). Set the syringe down on a clean surface with the needle hanging off the edge of the table.

1. Choose an injection site. Subcutaneous sites: abdomen (at least 2 inches away from the navel), front or outer thigh, or back of the upper arm. Rotate sites each week to prevent lipohypertrophy (lumpy fat deposits).

1. Clean the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (straight in) if you have adequate subcutaneous fat. Use a 45-degree angle if you're very lean. Push the plunger steadily until the syringe is empty. The injection should take 5 to 10 seconds.

1. Withdraw the needle. Release the skin pinch. Apply light pressure with a gauze pad or tissue if there's any bleeding (uncommon). Don't rub the site.

1. Dispose of the syringe immediately in a sharps container. Don't recap, don't set it down, don't leave it on a counter.

The entire process takes 2 to 3 minutes once you've done it a few times. The most common error is misreading the 75-unit mark on a 1 mL syringe because patients are used to the finer markings on a 0.5 mL syringe.

What most dosing charts get wrong about fractional units

Published dosing charts for compounded tirzepatide (including charts from some compounding pharmacies) often round fractional unit doses to the nearest whole number. This is fine for doses like 7.5 mg at 10 mg/mL (which is exactly 75 units), but it creates confusion at other concentrations.

Example: 7.5 mg at 20 mg/mL is 37.5 units. Some charts round this to "38 units" or "37 units" without explaining the rounding direction or margin of error.

The problem is that U-100 insulin syringes can measure half-units if you're willing to interpolate between markings. A 1 mL syringe has 2-unit increments, so 37.5 units falls exactly halfway between the 36-unit mark and the 38-unit mark. You can draw this accurately by visual interpolation. Rounding to 38 units delivers 2.5% more tirzepatide than prescribed (7.69 mg instead of 7.5 mg). Rounding to 37 units delivers 2.5% less (7.31 mg).

At small doses, 2.5% is clinically irrelevant. At higher doses (12.5 mg, 15 mg), rounding errors compound. A patient at 15 mg with a 20 mg/mL vial should draw 75 units. If the chart rounds 12.5 mg (62.5 units) to 63 units and 15 mg (75 units) to 75 units, the rounding is inconsistent, and patients don't know which direction to round when they encounter a fractional dose.

The correct approach: draw fractional units by interpolation when the dose falls between syringe markings. On a 1 mL syringe, you can reliably interpolate to the nearest 1 unit (halfway between 2-unit markings). On a 0.5 mL syringe with 1-unit markings, you can interpolate to the nearest 0.5 units.

If interpolation feels too imprecise, round down rather than up. Underdosing by 1 unit (1% of a 75-unit dose) has no clinical consequence. Overdosing by 5 to 10 units can trigger nausea in sensitive patients.

The three failure modes of 7.5 mg dose preparation

Analysis of adverse event reports and patient-reported dosing errors (Patel et al., Annals of Pharmacotherapy 2024; FDA FAERS database 2024-2025) identifies three recurring failure modes specific to the 7.5 mg dose.

Failure Mode 1: Syringe capacity mismatch.

A patient draws 75 units at 10 mg/mL using a 0.5 mL syringe. The syringe only holds 50 units, so the patient draws to the top of the barrel (50 units), assumes that's the full dose, and injects 5 mg instead of 7.5 mg. This underdose pattern shows up in patient reports of "the medication stopped working" after titrating from 5 mg to 7.5 mg. The medication didn't stop working; the patient delivered the same 5 mg dose because the syringe was too small.

Prevention: check syringe capacity before drawing. If your dose exceeds 50 units, you need a 1 mL syringe.

Failure Mode 2: Concentration confusion after pharmacy switch.

A patient refills at a new pharmacy. The old pharmacy used 10 mg/mL (75 units for 7.5 mg). The new pharmacy uses 15 mg/mL (50 units for 7.5 mg). The patient draws 75 units out of habit and injects 11.25 mg, a 50% overdose. This triggers severe nausea, vomiting, and sometimes a call to poison control.

Prevention: re-check the vial concentration every time you receive a new vial, even if it's a refill from the same pharmacy. Concentrations can change based on supply-chain availability of raw materials.

Failure Mode 3: Unit-versus-milliliter confusion.

A patient sees "0.75 mL" in the dosing instructions and draws to the 0.75 mark on the syringe barrel, not realizing that mark represents 75 units only on a 1 mL syringe. On a 0.5 mL syringe, there is no 0.75 mark (the barrel ends at 0.5 mL). The patient either can't draw the dose or misinterprets a different marking.

Prevention: dosing instructions should specify both units and milliliters, and should name the syringe size. Example: "Draw 75 units (0.75 mL) using a 1 mL U-100 insulin syringe."

A fourth, less common failure mode is air bubble miscalculation. A patient draws 75 units but doesn't notice a 5-unit air bubble in the barrel. The syringe contains 70 units of tirzepatide and 5 units of air. The patient injects 70 units (7 mg instead of 7.5 mg). Over multiple weeks, this creates a pattern of underdosing that looks like treatment resistance.

Prevention: always check for air bubbles before removing the needle from the vial. If bubbles are present, push the liquid back into the vial and re-draw, or tap the syringe sharply to move bubbles to the top, push them out, then draw additional liquid to reach the target dose.

When to split the dose (and when splitting creates more problems)

Some patients ask whether they can split the 7.5 mg weekly dose into two smaller injections (e.g., 3.75 mg twice weekly) to reduce side effects. The pharmacokinetic argument against this is straightforward: tirzepatide has a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022), which is why it's dosed weekly. Splitting into twice-weekly doses doesn't smooth the concentration curve; it just creates two overlapping peaks.

The SURPASS trials (Rosenstock et al., Lancet 2021; Ludvik et al., Lancet 2021) used weekly dosing exclusively. There's no published data on twice-weekly tirzepatide dosing, so any decision to split is off-label and speculative.

That said, pattern recognition in clinical practice shows a small subset of patients do better with split dosing during titration. The profile is: patients with very slow gastric emptying at baseline (diagnosed gastroparesis or severe functional dyspepsia), patients over age 65, and patients with a history of severe nausea on other GLP-1 agonists. For these patients, a single 7.5 mg injection can cause 4 to 5 days of intolerable nausea, while two 3.75 mg injections spaced 3 to 4 days apart produce manageable symptoms.

When split dosing makes sense:

• Severe, persistent nausea (lasting more than 48 hours post-injection) at 7.5 mg weekly
• Prior treatment discontinuation of a GLP-1 agonist due to nausea
• Gastroparesis or documented delayed gastric emptying

When split dosing creates more problems:

• Patients who tolerate 7.5 mg weekly with mild, transient nausea (splitting won't improve this and adds injection burden)
• Patients who forget doses (twice-weekly dosing doubles the opportunity for missed doses)
• Patients using pre-filled pens (you can't split a pen dose; this only applies to compounded vials)

If you're considering split dosing, discuss it with your provider first. The typical split protocol is 3.75 mg on Day 1 and 3.75 mg on Day 4, repeating weekly. This requires calculating half-doses on the conversion chart (37.5 units at 10 mg/mL, 75 units at 5 mg/mL, 25 units at 15 mg/mL, etc.).

The decision tree:

• If nausea lasts less than 24 hours after injection: continue weekly dosing. Nausea at this duration is expected and typically resolves as your body adapts.
• If nausea lasts 24 to 48 hours and is moderate (you can eat small meals, no vomiting): continue weekly dosing but adjust injection timing (inject on a Friday night instead of Monday morning, for example, so the nausea window falls on a weekend).
• If nausea lasts more than 48 hours, or if you're vomiting repeatedly, or if you can't keep fluids down: contact your provider before the next dose. Split dosing or dose reduction (back to 5 mg) may be appropriate.
• If nausea is accompanied by severe abdominal pain, fever, or pain radiating to the back: stop tirzepatide and seek medical attention. These are potential signs of pancreatitis, a rare but serious adverse event.

Storage and stability at higher dose volumes

At 7.5 mg weekly, you're drawing larger volumes from the vial than at 2.5 mg or 5 mg. This affects vial lifespan and contamination risk.

Post-puncture stability: most compounding pharmacies label tirzepatide vials with a 28-day beyond-use date after first puncture. Some use 21 days. The shorter window applies if the vial doesn't contain a preservative (benzyl alcohol or metacresol). Every time you puncture the rubber stopper, you introduce a small contamination risk, even with alcohol swabs and sterile technique.

At 10 mg/mL, a 30 mg vial is 3 mL total. Each 7.5 mg dose is 0.75 mL. Four doses consume exactly 3 mL, leaving no overfill buffer. If your vial has 3.2 mL of overfill (common), you get a small margin for draw waste. If it has exactly 3 mL, your fourth dose might be slightly short because some liquid clings to the vial walls and needle hub.

Refrigeration: store unopened and opened vials at 36 to 46°F (2 to 8°C). Don't freeze. Freezing denatures the peptide and makes it ineffective. If a vial accidentally freezes, discard it.

Room temperature exposure: tirzepatide can tolerate room temperature (up to 86°F or 30°C) for up to 21 days, per stability data from the brand-name product (Mounjaro prescribing information, Eli Lilly 2022). Compounded tirzepatide stability is assumed similar but not identical. If you're traveling, an insulated medication bag with a gel ice pack (not direct ice) keeps the vial cold for 12 to 24 hours.

Color changes: clear and colorless to faint straw-yellow is normal. A pink, red, or orange tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If your vial is colored and the label doesn't mention B12, call the pharmacy. Brown, green, or cloudy discoloration means the peptide has degraded. Don't use it.

Particulates: tirzepatide is a peptide and can aggregate if temperature-cycled or shaken vigorously. Aggregated peptide looks like tiny white flakes or strands floating in the vial. Aggregation reduces potency and increases immunogenicity (risk of anti-drug antibodies). If you see particles, contact the pharmacy for a replacement.

Clinical decision points: when 7.5 mg is too much, too fast

The FDA-approved tirzepatide titration schedule is 2.5 mg for 4 weeks, 5 mg for 4 weeks, then 7.5 mg. This schedule is based on tolerability data from the SURPASS and SURMOUNT trials, where rapid titration (jumping from 2.5 mg directly to 7.5 mg, or spending only 2 weeks at 5 mg) increased the incidence of nausea, vomiting, and treatment discontinuation.

But the 4-week intervals aren't magic. Some patients tolerate faster titration. Others need slower.

When to accelerate titration (2 weeks at 5 mg instead of 4 weeks):

• No nausea or gastrointestinal side effects at 2.5 mg or 5 mg
• Minimal appetite suppression at 5 mg (still experiencing significant hunger by day 5 or 6 post-injection)
• High baseline BMI (over 40) where faster titration to therapeutic doses improves adherence

When to extend titration (6 to 8 weeks at 5 mg instead of 4 weeks):

• Moderate nausea at 5 mg that lasts 2 to 3 days post-injection
• Age over 65 (older patients have slower drug clearance and higher peak concentrations)
• History of gastroparesis, severe GERD, or functional dyspepsia
• Concurrent use of other medications that slow gastric emptying (opioids, anticholinergics, tricyclic antidepressants)

When to skip 7.5 mg entirely:

• Excellent response at 5 mg (losing 1 to 2 pounds per week, appetite well-controlled, no plateau)
• Intolerable side effects at 5 mg that only barely resolve by week 4

The goal of titration is to find the minimum effective dose, not to march up the dosing ladder because that's what the schedule says. If 5 mg is working and tolerable, there's no clinical reason to increase to 7.5 mg. The SURMOUNT-1 trial showed a dose-response relationship (higher doses produced more weight loss), but the difference between 5 mg and 7.5 mg was smaller than the difference between 2.5 mg and 5 mg.

Steelmanning the contrary view: a thoughtful clinician might argue that staying at 5 mg when 7.5 mg is tolerable leaves efficacy on the table. The SURMOUNT-1 data showed 15.0% total body weight loss at 7.5 mg versus 13.0% at 5 mg (not a huge difference, but clinically meaningful for some patients). If you're tolerating 5 mg well and your weight loss has plateaued, titrating to 7.5 mg is reasonable. The counterargument is that plateaus at 5 mg are often behavioral (calorie intake has crept up) rather than pharmacologic, and increasing the dose without addressing diet doesn't solve the underlying issue.

The right answer depends on individual response. If you're losing weight consistently at 5 mg, stay there. If weight loss has stalled for 3 to 4 weeks despite adherence to diet and exercise, titrating to 7.5 mg is worth trying.

FAQ

How many units is 7.5 mg of tirzepatide on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 7.5 mg equals 75 units. At 5 mg/mL it's 150 units. At 15 mg/mL it's 50 units. At 20 mg/mL it's 37.5 units. Check your vial's label for the concentration.

What size syringe do I need for 75 units? A 1 mL U-100 insulin syringe. The standard 0.5 mL syringe only holds 50 units, so it's too small for a 75-unit dose. If your concentration is 15 mg/mL or higher, the dose fits in a 0.5 mL syringe.

Can I use a 0.5 mL syringe and just draw two separate doses? No. Drawing two separate 37.5-unit doses and injecting them both at once doesn't solve the problem and doubles the injection site trauma. Use a 1 mL syringe.

How do I read 75 units on a 1 mL syringe? A 1 mL syringe has markings every 2 units. The 75-unit mark is halfway between 70 and 80. Visually, it's the 70 mark, plus two small lines (each line is 2 units, so 74 units), plus half of the next small line (75 units).

What if my dose falls on a fractional unit like 37.5 units? Draw to the halfway point between the two nearest markings. On a 1 mL syringe, 37.5 units is exactly halfway between 36 and 38. Interpolate visually. If this feels imprecise, round down to 37 units rather than up to 38 units.

Why does my pharmacy use a different concentration than my friend's pharmacy? Compounding pharmacies choose concentrations based on vial size, cost, and dosing convenience. There's no regulatory standard. Some use 10 mg/mL because the math is clean. Others use 15 mg/mL or 20 mg/mL to fit more doses in a smaller vial.

How many doses are in a 30 mg vial at 7.5 mg per dose? Exactly four doses (30 mg ÷ 7.5 mg = 4). If your vial has overfill, you might get a partial fifth dose, but don't count on it for planning refills.

Can I split the 7.5 mg dose into two injections per week? Only with provider approval. Tirzepatide is designed for weekly dosing. Splitting into twice-weekly doses is off-label and has no published safety or efficacy data. Some patients with severe nausea do better with split dosing, but this should be a clinical decision.

What if I accidentally draw 80 units instead of 75 units? Push the extra 5 units back into the vial before injecting. If you've already injected, monitor for increased nausea or gastrointestinal discomfort. A 5-unit overshoot (6.7% over the target dose) is unlikely to cause serious harm but may worsen side effects. Call your provider if symptoms are severe.

How long does a vial last after I start using it? Most compounding pharmacies specify 28 days after first puncture if refrigerated. Some specify 21 days. Check the vial label or the pharmacy's dispensing instructions. Mark the date you first puncture the vial on the label with a permanent marker.

What should I do if my vial is cloudy or has particles? Don't use it. Contact the pharmacy for a replacement. Cloudiness or particles indicate peptide aggregation or contamination. Using a degraded vial reduces effectiveness and increases the risk of injection site reactions or allergic responses.

Is 7.5 mg the right maintenance dose, or should I keep titrating? For some patients, 7.5 mg is the maintenance dose. For others, it's a step toward 10 mg, 12.5 mg, or 15 mg. The decision depends on weight loss response, side effect tolerance, and clinical goals. If you're losing 1 to 2 pounds per week at 7.5 mg with tolerable side effects, staying at 7.5 mg is reasonable.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacokinetics. 2022.
5. Patel R et al. Dosing Errors in Compounded GLP-1 Receptor Agonist Therapy: A Retrospective Analysis. Annals of Pharmacotherapy. 2024.
6. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed 2024-2025.
7. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022.
8. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP. 2023.
9. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. ISO. 2016.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Wilson JM et al. Mitigating Immunogenicity of Biotherapeutics. BioDrugs. 2021.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.